SCHEMBL2332583

SCHEMBL2332583

CCCCC(C)OC(=O)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.56
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
CA2 P00918 3/20 0.44
CA1 P00915 2/20 0.44
ALDH1A1 P00352 1/20 0.41
LMNA P02545 2/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.39
NAAA Q02083 1/20 0.38
EPHX2 P34913 1/20 0.38
CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10772690 0.94 FAAH (0.64) FAAHCNR1CNR2CA1ALDH1A1
SCHEMBL7223847 0.92 FAAH (0.67) FAAHCNR1CNR2ALDH1A1LMNA
SCHEMBL2363284 0.92 FAAH (0.67) FAAHCNR1CNR2ALDH1A1LMNA
SCHEMBL19687794 0.92 FAAH (0.67) FAAHCNR1CNR2ALDH1A1LMNA
SCHEMBL14296416 0.86 FAAH (0.46) FAAHCNR1CNR2CA2CA1
SCHEMBL880134 0.86 FAAH (0.46) FAAHCNR1CNR2CA2CA1
SCHEMBL14296417 0.86 FAAH (0.46) FAAHCNR1CNR2CA2CA1
SCHEMBL4838991 0.85 FAAH (0.54) FAAHCNR1CNR2CA2CA1
SCHEMBL3223549 0.85 FAAH (0.54) FAAHCNR1CNR2CA2CA1
SCHEMBL18597140 0.85 FAAH (0.54) FAAHCNR1CNR2CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110981873-B Preparation method for synthesizing pyrroloquinoline quinone by five-step method 江西农业大学 2025-01-24 CN claimed
CN-110981873-B Preparation method for synthesizing pyrroloquinoline quinone by five-step method 江西农业大学 2025-01-24 CN disclosed
US-20170196848-A1 Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives ALKERMES PHARMA IRELAND LTD (IE) 2017-07-13 US disclosed
US-20170196848-A1 Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives ALKERMES PHARMA IRELAND LTD (IE) 2017-07-13 US disclosed
US-9585965-B2 Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives ALKERMES PHARMA IRELAND LIMITED (IE) 2017-03-07 US disclosed
US-20150320875-A1 Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives ALKERMES PHARMA IRELAND LTD (IE) 2015-11-12 US disclosed
US-9072788-B2 Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives ALKERMES PHARMA IRELAND LIMITED (IE) 2015-07-07 US disclosed
EP-2358345-B1 COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND A POWDER DYE ORÉAL L (FR) 2015-04-08 EP disclosed
EP-2358347-B1 COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND A NON-IONIC SILICONE SURFACTANT OREAL (FR) 2014-02-26 EP disclosed
US-20110319422-A1 PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES ALKERMES, INC. (US) 2011-12-29 US disclosed
WO-2010063955-A2 COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND A NON-VOLATILE OIL L'OREAL (FR) 2010-06-10 WO disclosed
WO-2010063958-A2 COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND A VOLATILE SOLVENT L'OREAL (FR) 2010-06-10 WO disclosed
WO-2009080964-A2 COSMETIC PROCESS USING A COMPOSITION COMPRISING A SILOXANE RESIN AND A NONVOLATILE OIL L'OREAL (FR) 2009-07-02 WO disclosed
WO-2009080952-A2 COSMETIC MAKE-UP AND/OR CARE METHOD USING A SILOXANE RESIN AND A NON-VOLATILE OIL L'OREAL (FR) 2009-07-02 WO disclosed
US-20090062358-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS CANO IVAN COLLADO 2009-03-05 US disclosed
EP-1335908-B1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS LILLY CO ELI (US) 2008-02-13 EP disclosed
US-7304062-B2 Peroxisome proliferator activated receptor alpha agonists ELI LILLY AND COMPANY (US) 2007-12-04 US disclosed
US-20040102500-A1 Peroxisome proliferator activated receptor alpha agonists CANO IVAN COLLADO (ES) 2004-05-27 US disclosed
EP-1335908-A2 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS ELI LILLY AND COMPANY (US) 2003-08-20 EP disclosed
WO-2002038553-A2 TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS ELI LILLY AND COMPANY (US) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102500-A1 Peroxisome proliferator activated receptor alpha agonists PPARG, PPARA, PPARD FAAH 368/4885CNR1 4/4885CNR2 5/4885
US-20150320875-A1 Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives PHPT1, SI, CA6 FAAH 807/4885CNR1 280/4885CNR2 263/4885
US-20170196848-A1 Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives PHPT1, SI, CA6 FAAH 807/4885CNR1 280/4885CNR2 263/4885
US-20110319422-A1 PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES PHPT1, SI, CA6 FAAH 807/4885CNR1 280/4885CNR2 263/4885
US-20090062358-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS PPARG, PPARA, PPARD FAAH 81/4885CNR1 6/4885CNR2 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.